Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | JMJD6 | Q6NYC1 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507042 | 0.79 | KMT2A (0.38) | KEAP1KMT2AKDM4CKDM5BJMJD6 | |
| SCHEMBL20892184 | 0.79 | — | — | |
| SCHEMBL2629337 | 0.77 | — | — | |
| SCHEMBL26916681 | 0.77 | — | — | |
| SCHEMBL1481824 | 0.73 | JMJD6 (0.39) | KMT2AKDM4CKDM5BJMJD6NPC1 | |
| SCHEMBL31041232 | 0.72 | — | — | |
| SCHEMBL9386068 | 0.72 | KDM4C (0.35) | KEAP1KMT2AKDM4CKDM5BJMJD6 | |
| SCHEMBL12535839 | 0.72 | KDM4C (0.38) | KEAP1KMT2AKDM4CKDM5BJMJD6 | |
| SCHEMBL84431 | 0.72 | — | — | |
| SCHEMBL1086136 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KEAP1 702/4885KMT2A 278/4885KDM4C 835/4885 |
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | KEAP1 692/4885KMT2A 560/4885KDM4C 1686/4885 |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | KEAP1 692/4885KMT2A 560/4885KDM4C 1686/4885 |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | KEAP1 692/4885KMT2A 560/4885KDM4C 1686/4885 |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | KEAP1 692/4885KMT2A 606/4885KDM4C 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.